Department of Cardiovascular Diseases, University Hospital of Pisa, Via Roma 67, Pisa, Italy.
Europace. 2012 Apr;14(4):515-21. doi: 10.1093/europace/eur339. Epub 2011 Oct 28.
Few data are available on cardiac resynchronization therapy (CRT) after coronary sinus (CS) lead extraction. We aimed to evaluate the feasibility and mid-term outcome of transvenous CS lead reimplantation in a tertiary referral centre.
We enrolled all patients who were referred to our hospital for CS lead removal from December 2000 through to May 2009 and were transvenously reimplanted with a CRT system before June 2009. One-year follow-up was performed to evaluate the incidence of infections, malfunctions, and mortality. We studied 113 consecutive patients undergoing successful CS lead extraction; 90 patients (75 male, mean age 69.2, range 35-84) underwent CS lead reimplantation (success rate: 95.6%; right-sided approach: 64.4%). In these patients, cardiac device infection was the usual indication for extraction (74.4%) and the subsequent reimplantation was performed after a median time of 3 days. The coronary sinus lead was usually positioned in the left ventricular (LV) postero-lateral region (62.2%); two procedures were required in two cases (2.2%). Balloon angioplasty was necessary for two patients (failure in one), whereas for the others we used a conventional implant technique. During follow-up, we observed four cases (4.4%) of local infection and six cases (6.7%) of system malfunction, requiring reintervention (two cases during the same hospitalization). One-year mortality was 5.5%.
Left ventricular lead reimplantation is in our experience an effective and safe procedure, also in the case of right-sided approach. During follow-up, 1-year mortality was particularly low, whereas overall infection rate was higher than first implant procedures.
关于经冠状窦(CS)导线拔除后的心脏再同步治疗(CRT),目前仅有少量数据。我们旨在评估在一家三级转诊中心经静脉 CS 导线重新植入的可行性和中期结果。
我们纳入了所有于 2000 年 12 月至 2009 年 5 月因 CS 导线移除而转至我院的患者,并于 2009 年 6 月前经静脉重新植入 CRT 系统。进行了为期 1 年的随访,以评估感染、故障和死亡率的发生率。我们研究了 113 例连续接受成功 CS 导线拔除的患者;90 例(75 例男性,平均年龄 69.2 岁,范围 35-84 岁)接受 CS 导线重新植入(成功率:95.6%;右侧入路:64.4%)。在这些患者中,心脏器械感染是最常见的拔除指征(74.4%),随后在中位时间 3 天后进行了再植入。CS 导线通常放置在左心室(LV)后侧区域(62.2%);在 2 例患者(2.2%)中需要进行 2 次手术。有 2 例患者(1 例失败)需要球囊血管成形术,而对于其他患者,我们采用了常规植入技术。在随访期间,我们观察到 4 例(4.4%)局部感染和 6 例(6.7%)系统故障,需要再次干预(2 例在同一住院期间)。1 年死亡率为 5.5%。
在我们的经验中,左心室导线再植入是一种有效且安全的程序,即使采用右侧入路也是如此。在随访期间,1 年死亡率特别低,而总感染率高于初次植入手术。